Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Immunologic Research
Erschienen in: Immunologic Research 4/2016

06.05.2016 | Original Article

VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells

verfasst von: Xueyan Ren, Wei Xie, Youfu Wang, Menghuai Xu, Fang Liu, Mingying Tang, Chenchen Li, Min Wang, Juan Zhang

Erschienen in: Immunologic Research | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

MHC class I polypeptide-related sequence A (MICA), which is normally expressed on cancer cells, activates NK cells via NK group 2-member D pathway. However, some cancer cells escape NK-mediated immune surveillance by shedding membrane MICA causing immune suppression. To address this issue, we designed an antibody-MICA fusion targeting tumor-specific antigen (vascular endothelial growth factor receptor 2, VEGFR2) based on our patented antibody (mAb04) against VEGFR2. In vitro results demonstrate that the fusion antibody retains both the antineoplastic and the immunomodulatory activity of mAb04. Further, we revealed that it enhanced NK-mediated immunosurveillance against K562 cells through increasing degranulation and cytokine production of NK cells. The overall data suggest our new fusion protein provides a promising approach for cancer-targeted immunotherapy and has prospects for potential application of chronic myeloid leukemia.
Literatur
1.
Wang Y, Chen C, Dong F, Ma S, Xu J, Gong Y, et al. NK cells play a significant role in immunosurveillance at the early stage of MLL-AF9 acute myeloid leukemia via CD226/CD155 interactions. Sci China Life Sci. 2015;58:1288–98.CrossRefPubMed
2.
Fionda C, Soriani A, Zingoni A, Santoni A, Cippitelli M. NKG2D and DNAM-1 ligands: molecular targets for NK cell-mediated immunotherapeutic intervention in multiple myeloma. BioMed Res Int. 2015;2015:178698.CrossRefPubMedPubMedCentral
3.
4.
Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, et al. Anti-tumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science (New York, NY). 2015;348(6230):136–9.CrossRef
5.
Gonzalez-Foruria I, Santulli P, Chouzenoux S, Carmona F, Batteux F, Chapron C. Soluble ligands for the NKG2D receptor are released during endometriosis and correlate with disease severity. PLoS ONE. 2015;10(3):e0119961.CrossRefPubMedPubMedCentral
6.
Chitadze G, Bhat J, Lettau M, Janssen O, Kabelitz D. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol. 2013;78(2):120–9.CrossRefPubMed
7.
Sanchez-Correa B, Morgado S, Gayoso I, Bergua JM, Casado JG, Arcos MJ, et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother (CII). 2011;60(8):1195–205.CrossRef
8.
Chen D, Gyllensten U. MICA polymorphism: biology and importance in cancer. Carcinogenesis. 2014;35(12):2633–42.CrossRefPubMed
9.
Hardan I, Stanevsky A, Volchek Y, Tohami T, Amariglio N, Trakhtenbrot L, et al. Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia. Cytokine. 2012;57(2):290–3.CrossRefPubMed
10.
Talpaz M, Mercer J, Hehlmann R. The interferon-alpha revival in CML. Ann Hematol. 2015;94(Suppl 2):S195–207.CrossRefPubMed
11.
Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc. 2015;90(10):1440–54.CrossRefPubMed
12.
Held SA, Heine A, Mayer KT, Kapelle M, Wolf DG, Brossart P. Advances in immunotherapy of chronic myeloid leukemia CML. Curr Cancer Drug Targets. 2013;13(7):768–74.CrossRefPubMed
13.
14.
Doan V, Wang A, Prescott H. Bosutinib for the treatment of chronic myeloid leukemia. Am J Health Syst Pharm (AJHP). 2015;72(6):439–47.CrossRef
15.
Tanizawa A. Optimal management for pediatric chronic myeloid leukemia. Pediatr Int. 2016;58:171–9.CrossRefPubMed
16.
Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol. 2011;29(20):2827–32.CrossRefPubMed
17.
Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk. 2015;15(6):323–34.CrossRefPubMed
18.
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–96.CrossRefPubMed
19.
Balabanov S, Braig M, Brummendorf TH. Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. Drug Discov Today Technol. 2014;11:89–99.CrossRefPubMed
20.
Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210–8.CrossRefPubMed
21.
Rea D. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Ann Hematol. 2015;94(Suppl 2):S149–58.CrossRefPubMed
22.
Jain NA, Ito S, Tian X, Kurlander R, Battiwalla M, Lu K, et al. Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. Bone Marrow Transplant. 2015;50(2):189–96.CrossRefPubMed
23.
Maffei R, Martinelli S, Castelli I, Santachiara R, Zucchini P, Fontana M, et al. Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leuk Res. 2010;34(3):312–21.CrossRefPubMed
24.
Dong X, Han ZC, Yang R. Angiogenesis and anti-angiogenic therapy in hematologic malignancies. Crit Rev Oncol/Hematol. 2007;62(2):105–18.CrossRef
25.
Mineo M, Garfield SH, Taverna S, Flugy A, De Leo G, Alessandro R, et al. Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion. Angiogenesis. 2012;15(1):33–45.CrossRefPubMed
26.
Taverna S, Flugy A, Saieva L, Kohn EC, Santoro A, Meraviglia S, et al. Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis. Int J Cancer. 2012;130(9):2033–43.CrossRefPubMed
27.
Lee JJ, Chung IJ, Park MR, Ryang DW, Park CS, Kim HJ. Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia. Leuk Res. 2001;25(12):1067–73.CrossRefPubMed
28.
Zhou HJ, Wang WQ, Wu GD, Lee J, Li A. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol. 2007;47(2–3):131–8.CrossRefPubMed
29.
Xie W, Li D, Zhang J, Li Z, Acheampong DO, He Y, et al. Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2. Cancer Immunol Immunother (CII). 2014;63(9):877–88.CrossRef
30.
Chen H, Shen YF, Gong F, Yang GH, Jiang YQ, Zhang R. Expression of VEGF and its effect on cell proliferation in patients with chronic myeloid leukemia. Eur Rev Med Pharmacol Sci. 2015;19(19):3569–73.PubMed
31.
Vidovic A, Jankovic G, Tomin D, Perunicic-Jovanovic M, Djunic I, Djurasinovic V, et al. Prognostic significance of cellular vascular endothelial growth factor (VEGF) expression in the course of chronic myeloid leukaemia. Srp Arh Celok Lek. 2009;137(7–8):379–83.CrossRefPubMed
32.
Verstovsek S, Lunin S, Kantarjian H, Manshouri T, Faderl S, Cortes J, et al. Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res. 2003;27(7):661–9.CrossRefPubMed
33.
Kloss S, Chambron N, Gardlowski T, Weil S, Koch J, Esser R, et al. Cetuximab reconstitutes pro-inflammatory cytokine secretions and tumor-infiltrating capabilities of sMICA-inhibited NK cells in HNSCC tumor spheroids. Front Immunol. 2015;6:543.CrossRefPubMedPubMedCentral
34.
Kloss S, Chambron N, Gardlowski T, Arseniev L, Koch J, Esser R, et al. Increased sMICA and TGFbeta levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells. Oncoimmunology. 2015;4(11):e1055993.CrossRefPubMedPubMedCentral
35.
Kong L, Bhatt AR, Demny AB, Coats DK, Li A, Rahman EZ, et al. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2015;56(2):956–61.CrossRefPubMed
36.
Bogusz J, Majchrzak A, Medra A, Cebula-Obrzut B, Robak T, Smolewski P. Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells. Postepy Hig Med Dosw (Online). 2013;67:107–18.CrossRef
37.
Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, et al. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch–Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Blood. 2012;120(24):4706–11.CrossRefPubMed
38.
Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, et al. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol. 2010;41(3):375–84.CrossRefPubMed
39.
Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7(5):575–83.CrossRefPubMed
Metadaten
Titel
VEGFR2-targeted fusion antibody improved NK cell-mediated immunosurveillance against K562 cells
verfasst von
Xueyan Ren
Wei Xie
Youfu Wang
Menghuai Xu
Fang Liu
Mingying Tang
Chenchen Li
Min Wang
Juan Zhang
Publikationsdatum
06.05.2016
Verlag
Springer US
Erschienen in
Immunologic Research / Ausgabe 4/2016
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-016-8800-3

Weitere Artikel der Ausgabe 4/2016

Immunologic Research 4/2016 Zur Ausgabe

Original Article

Curdlan blocks the immune suppression by myeloid-derived suppressor cells and reduces tumor burden

Original Article

Generation of regulatory dendritic cells after treatment with paeoniflorin

Original Article

Combined immunodeficiency in a patient with mosaic monosomy 21

Review

Protein tyrosine phosphatase SHP-1: resurgence as new drug target for human autoimmune disorders

Original Article

The role of HSP27 in RACK1-mediated PKC activation in THP-1 cells

Original Article

Majoon ushba, a polyherbal compound, suppresses pro-inflammatory mediators and RANKL expression via modulating NFкB and MAPKs signaling pathways in fibroblast-like synoviocytes from adjuvant-induced arthritic rats

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise